Renal-cell carcinoma - Molecular pathways and therapies

被引：208

作者：

Brugarolas, James ^{[1
]}

机构：

[1] Univ Texas, SW Med Sch, Div Hematol Oncol, Dallas, TX 75235 USA

[2] Univ Texas, SW Med Ctr, Simmons Comprehens Canc Ctr, Dallas, TX USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2007年 / 356卷 / 02期

关键词：

D O I：

10.1056/NEJMe068263

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：185 / 187

页数：3

共 12 条

[1] TSC2 regulates VEGF through mTOR-dependent and -independent pathways
Brugarolas, JB
Vazquez, F
Reddy, A
Sellers, WR
Kaelin, WG
[J]. CANCER CELL, 2003, 4 (02) : 147 - 158
[2] Sorafenib in advanced clear-cell renal-cell carcinoma
Escudier, Bernard
Eisen, Tim
Stadler, Walter M.
Szczylik, Cezary
Oudard, Stephane
Siebels, Michael
Negrier, Sylvie
Chevreau, Christine
Solska, Ewa
Desai, Apurva A.
Rolland, Frederic
Demkow, Tomasz
Hutson, Thomas E.
Gore, Martin
Freeman, Scott
Schwartz, Brian
Shan, Minghua
Simantov, Ronit
Bukowski, Ronald M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 125 - 134
[3] A small molecule-kinase interaction map for clinical kinase inhibitors
Fabian, MA
Biggs, WH
Treiber, DK
Atteridge, CE
Azimioara, MD
Benedetti, MG
Carter, TA
Ciceri, P
Edeen, PT
Floyd, M
Ford, JM
Galvin, M
Gerlach, JL
Grotzfeld, RM
Herrgard, S
Insko, DE
Insko, MA
Lai, AG
Lélias, JM
Mehta, SA
Milanov, ZV
Velasco, AM
Wodicka, LM
Patel, HK
Zarrinkar, PP
Lockhart, DJ
[J]. NATURE BIOTECHNOLOGY, 2005, 23 (03) : 329 - 336
[4] RESULTS OF TREATMENT OF 255 PATIENTS WITH METASTATIC RENAL-CELL CARCINOMA WHO RECEIVED HIGH-DOSE RECOMBINANT INTERLEUKIN-2 THERAPY
FYFE, G
FISHER, RI
ROSENBERG, SA
SZNOL, M
PARKINSON, DR
LOUIE, AC
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) : 688 - 696
[5] Hudes G, 2006, J CLIN ONCOL, V24, p930S
[6] Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
Hudson, CC
Liu, M
Chiang, GG
Otterness, DM
Loomis, DC
Kaper, F
Giaccia, AJ
Abraham, RT
[J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (20) : 7004 - 7014
[7] The von Hippel-Lindau tumor suppressor gene and kidney cancer
Kaelin, WG
[J]. CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6290S - 6295S
[8] Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth
Kondo, K
Kim, WY
Lechpammer, M
Kaelin, WG
[J]. PLOS BIOLOGY, 2003, 1 (03): : 439 - 444
[9] mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
Majumder, PK
Febbo, PG
Bikoff, R
Berger, R
Xue, Q
McMahon, LM
Manola, J
Brugarolas, J
McDonnell, TJ
Golub, TR
Loda, M
Lane, HA
Sellers, WR
[J]. NATURE MEDICINE, 2004, 10 (06) : 594 - 601
[10] Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Motzer, Robert J.
Hutson, Thomas E.
Tomczak, Piotr
Michaelson, M. Dror
Bukowski, Ronald M.
Rixe, Olivier
Oudard, Stephane
Negrier, Sylvie
Szczylik, Cezary
Kim, Sindy T.
Chen, Isan
Bycott, Paul W.
Baum, Charles M.
Figlin, Robert A.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) : 115 - 124

← 1 2 →